Therefore, the high, sustained levels of IL-11 observed in patients with severe AF are likely not just a passive response to TGF-β1 but are actively maintained by this pathological amplification loop, reframing IL-11 as a central driver of disease chronicity and a particularly compelling therapeutic target. Here, TGFB1 is linked to atrial fibrillation.